Jim Wassil Sells 2,250 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.86, for a total value of $121,185.00. Following the completion of the sale, the chief operating officer owned 157,541 shares of the company’s stock, valued at approximately $8,485,158.26. This trade represents a 1.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total value of $126,742.50.
• On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $49.52, for a total value of $111,420.00.

Vaxcyte Stock Up 5.3%

Shares of PCVX stock opened at $58.89 on Friday. The firm has a market capitalization of $8.50 billion, a price-to-earnings ratio of -7.72 and a beta of 1.23. The stock has a fifty day moving average of $53.72 and a 200 day moving average of $55.19. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the previous year, the company earned ($1.22) EPS. Equities research analysts anticipate that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Smartleaf Asset Management LLC boosted its stake in Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the period. Capital Advisors Ltd. LLC bought a new position in shares of Vaxcyte during the first quarter valued at approximately $58,000. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Vaxcyte by 22,500.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Zacks Research downgraded shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Hold” and an average price target of $86.00.

Vaxcyte News Roundup

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss beat expectations: Vaxcyte reported second-quarter 2026 EPS of negative $1.97, better than analysts’ consensus estimate of negative $2.06. However, the loss was wider than the negative $1.22 reported in the year-earlier quarter. Vaxcyte quarterly earnings release
• Positive Sentiment: Multiple clinical catalysts are ahead: Topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 are expected in the first half of 2027, while infant VAX-31 data are expected by the end of the first half of 2027. Vaxcyte second-quarter business update
• Positive Sentiment: Strong liquidity supports development: Vaxcyte held approximately $2.5 billion in cash, cash equivalents and investments at June 30, 2026. The balance sheet reduces near-term financing concerns as the company advances its late-stage vaccine programs and VAX-A1.
• Neutral Sentiment: Institutional ownership remains high: Several funds, including Royal Bank of Canada, UBS Asset Management and Cetera Investment Advisers, increased their positions recently. Institutional investors and hedge funds collectively own approximately 96.8% of outstanding shares.
• Negative Sentiment: Executives reported stock sales: The CFO, COO and another insider sold a combined 29,250 shares worth roughly $1.6 million. The transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may still weigh modestly on sentiment. Vaxcyte insider selling report
• Negative Sentiment: Losses are expected to continue: Analysts forecast a full-year 2026 loss of approximately $7.91 per share, underscoring Vaxcyte’s dependence on successful clinical execution and future commercialization.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.